Douglas Godshall - Oct 16, 2023 Form 4 Insider Report for Shockwave Medical, Inc. (SWAV)

Signature
s/ Wade Estey, as attorney-in-fact for Douglas Godshall
Stock symbol
SWAV
Transactions as of
Oct 16, 2023
Transactions value $
-$1,973,661
Form type
4
Date filed
10/17/2023, 08:10 PM
Previous filing
Sep 19, 2023
Next filing
Nov 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SWAV Common Stock Options Exercise $34.2K +10K +7.06% $3.42 152K Oct 16, 2023 Direct F1
transaction SWAV Common Stock Sale -$38.9K -200 -0.13% $194.59 151K Oct 16, 2023 Direct F1, F2
transaction SWAV Common Stock Sale -$59.1K -300 -0.2% $197.00 151K Oct 16, 2023 Direct F1, F3
transaction SWAV Common Stock Sale -$119K -600 -0.4% $198.64 151K Oct 16, 2023 Direct F1, F4
transaction SWAV Common Stock Sale -$1.1M -5.5K -3.65% $200.00 145K Oct 16, 2023 Direct F1, F5
transaction SWAV Common Stock Sale -$60.4K -300 -0.21% $201.29 145K Oct 16, 2023 Direct F1, F6
transaction SWAV Common Stock Sale -$254K -1.25K -0.87% $202.86 143K Oct 16, 2023 Direct F1, F7
transaction SWAV Common Stock Sale -$376K -1.85K -1.29% $203.60 142K Oct 16, 2023 Direct F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SWAV Stock Option Options Exercise $0 -10K -2.9% $0.00 335K Oct 16, 2023 Common Stock 10K $3.42 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023.
F2 All reported securities were sold at a price of $194.59.
F3 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $196.93 to $197.15. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $198.35 to $199.01. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F5 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $199.63 to $200.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F6 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $200.87 to $201.61. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F7 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $202.21 to $203.14. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F8 The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $203.22 to $204.04. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F9 Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares vested in equal monthly installments.